Golimumab is a recombinant human monoclonal antibody that selectively binds to and neutralizes tumor necrosis factor-alpha (TNF-α). It is a fully human IgG1κ antibody used as a biological therapeutic for several inflammatory and autoimmune disorders.
Golimumab is marketed as Simponi and is administered by subcutaneous injection. It is also available in combination with methotrexate for certain indications.
Golimumab is a specialized biological pharmaceutical API requiring recombinant mammalian-cell production, downstream purification and extensive protein characterization. Quality control differs substantially from conventional small-molecule APIs and includes protein identity, purity, aggregation, charge variants, glycosylation and biological activity.
Product Name: Golimumab
Brand: Simponi
Molecule Type: Recombinant human monoclonal antibody
Antibody Class: IgG1κ
Target: Tumor Necrosis Factor-alpha (TNF-α)
Drug Class: TNF Inhibitor
Therapeutic Class: Immunosuppressant / Biologic
Therapeutic Area: Rheumatology / Immunology
Golimumab binds with high affinity to soluble and transmembrane TNF-α, preventing TNF-α from interacting with its receptors. TNF-α is an important inflammatory cytokine involved in the pathogenesis of several chronic inflammatory diseases.
By neutralizing TNF-α activity, golimumab reduces inflammatory signaling and downstream immune-mediated tissue damage.
Golimumab is used for the treatment of certain inflammatory disorders, including:
Approved indications can vary according to the regulatory authority and product labeling.
Excessive TNF-α signaling contributes to chronic inflammation in several autoimmune disorders. Golimumab provides targeted cytokine inhibition by binding TNF-α, thereby reducing inflammatory activity.
Golimumab is a complex recombinant protein and does not have a conventional small-molecule molecular formula. It is an approximately 150 kDa glycoprotein consisting of two heavy chains and two light chains.
As a biological molecule, characterization focuses on molecular mass, amino-acid sequence, glycosylation, aggregation, charge heterogeneity, purity and biological activity.
Golimumab quality evaluation may include:
Golimumab drug substance and finished biological products require controlled temperature storage and protection from light and conditions that may compromise protein stability. Exact storage requirements should follow validated stability data and the applicable approved product specification.
Golimumab is an established anti-TNF biological therapeutic and is important in pharmaceutical research involving inflammatory cytokine signaling, autoimmune disease and targeted immunomodulation.
Golimumab is a fully human recombinant IgG1κ monoclonal antibody targeting TNF-α. It is primarily used in inflammatory and autoimmune disorders including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis. Because it is a complex biological molecule, its quality assessment relies on advanced protein characterization and biological potency testing.
| Parameter | Specification |
|---|---|
| pH (1% Solution) | 5.0 – 6.0 |